Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma:

Elie Rassy; Ronan Flippot; Laurence Albiges

doi:10.1177/1758835920907504

Rassy, Elie; Flippot, Ronan; Albiges, Laurence

Therapeutic Advances in Medical Oncology , Volume 12: 1 – Mar 18, 2020

Abstract

The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have improved outcomes of patients and modified the natural history of mRCC. Clinical investigations have focused on evaluating combination regimens containing ICIs and VEGFR-directed TKIs. Namely, the combinations of axitinib plus pembrolizumab (KEYNOTE-426) and axitinib plus avelumab (JAVELIN RENAL 101) have shown improved outcomes compared with sunitinib in treatment-naïve patients with mRCC. In this review, we discuss the clinical data of single-agent TKIs and ICIs in mRCC and the rationale for the combination ICIs and TKIs based on preclinical and clinical evidence. We also explore the current challenges for regimen selection and development of predictive biomarkers.

References (149)

( AtkinsMBPlimackERPuzanovI, et al Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 2018; 19: 405–415.29439857)

AtkinsMBPlimackERPuzanovI, et al Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 2018; 19: 405–415.29439857, AtkinsMBPlimackERPuzanovI, et al Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 2018; 19: 405–415.29439857

( EscudierBPortaCSchmidingerM, et al Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706–720.30788497)

EscudierBPortaCSchmidingerM, et al Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706–720.30788497

EscudierBPortaCSchmidingerM, et al Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706–720.30788497, EscudierBPortaCSchmidingerM, et al Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706–720.30788497

Matthew Young, T. Mitchell, F. Braga, M. Tran, B. Stewart, J. Ferdinand, G. Collord, R. Botting, Dorin-Mirel Popescu, K. Loudon, R. Vento-Tormo, Emily Stephenson, A. Cagan, Sarah Farndon, Martin Velasco-Herrera, C. Guzzo, N. Richoz, L. Mamanova, T. Aho, J. Armitage, Antony Riddick, I. Mushtaq, Stephen Farrell, D. Rampling, James Nicholson, A. Filby, Johanna Burge, S. Lisgo, P. Maxwell, S. Lindsay, A. Warren, G. Stewart, N. Sebire, N. Coleman, M. Haniffa, S. Teichmann, M. Clatworthy, S. Behjati (2018)

Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors

Science, 361

D. McDermott, M. Huseni, M. Atkins, R. Motzer, B. Rini, B. Escudier, L. Fong, R. Joseph, S. Pal, J. Reeves, M. Sznol, J. Hainsworth, W. Rathmell, W. Stadler, Thomas Hutson, M. Gore, A. Ravaud, S. Bracarda, C. Suarez, R. Danielli, V. Gruenwald, T. Choueiri, D. Nickles, S. Jhunjhunwala, E. Piault-Louis, A. Thobhani, J. Qiu, Daniel Chen, P. Hegde, C. Schiff, G. Fine, T. Powles (2018)

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Nature Medicine, 24

( YasudaSShoMYamatoI, et al Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013; 172: 500–506.23600839)

YasudaSShoMYamatoI, et al Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013; 172: 500–506.23600839, YasudaSShoMYamatoI, et al Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013; 172: 500–506.23600839

( BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.30207593)

BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.30207593, BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.30207593

( HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230)

HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230

HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230, HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.21376230

( AlbigesLPowlesTStaehlerM, et al Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 2019; 76: 151–156.31151678)

AlbigesLPowlesTStaehlerM, et al Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 2019; 76: 151–156.31151678, AlbigesLPowlesTStaehlerM, et al Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 2019; 76: 151–156.31151678

H. Hammers, E. Plimack, J. Infante, B. Rini, D. McDermott, L. Lewis, M. Voss, P. Sharma, S. Pal, A. Razak, C. Kollmannsberger, D. Heng, J. Spratlin, M. McHenry, A. Amin (2017)

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 34

T. Voron, O. Colussi, E. Marcheteau, S. Pernot, M. Nizard, Anne-Laure Pointet, Sabrina Latreche, S. Bergaya, N. Benhamouda, Corinne Tanchot, C. Stockmann, P. Combe, A. Berger, F. Zinzindohoué, H. Yagita, E. Tartour, J. Taieb, M. Terme (2015)

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

The Journal of Experimental Medicine, 212

R. Motzer, Thomas Hutson, D. Cella, J. Reeves, R. Hawkins, Jun Guo, P. Nathan, M. Staehler, P. Souza, J. Merchan, E. Boleti, K. Fife, Jie Jin, Robert Jones, H. Uemura, U. Giorgi, U. Harmenberg, Jinwan Wang, C. Sternberg, K. Deen, L. McCann, M. Hackshaw, R. Crescenzo, L. Pandite, T. Choueiri (2013)

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

The New England journal of medicine, 369 8

( MotzerRJTannirNMMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277–1290.29562145)

MotzerRJTannirNMMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277–1290.29562145

MotzerRJTannirNMMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277–1290.29562145, MotzerRJTannirNMMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277–1290.29562145

B. Curti (2018)

Immunotherapy in Advanced Renal Cancer - Is Cure Possible?

The New England journal of medicine, 378 14

Daniel Chen, I. Mellman (2013)

Oncology meets immunology: the cancer-immunity cycle.

Immunity, 39 1

( DudaniSGrahamJWellsJC, et al First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium. Eur Urol 2019; 76: 861–867.31445844)

DudaniSGrahamJWellsJC, et al First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium. Eur Urol 2019; 76: 861–867.31445844, DudaniSGrahamJWellsJC, et al First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium. Eur Urol 2019; 76: 861–867.31445844

( YoungMDMitchellTJVieira BragaFA, et al Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 2018; 361: 594–599.30093597)

YoungMDMitchellTJVieira BragaFA, et al Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 2018; 361: 594–599.30093597

YoungMDMitchellTJVieira BragaFA, et al Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 2018; 361: 594–599.30093597, YoungMDMitchellTJVieira BragaFA, et al Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 2018; 361: 594–599.30093597

Thomas Hutson (2011)

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.

The oncologist, 16 Suppl 2

M. Ruf, H. Moch, P. Schraml (2016)

PD‐L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

International Journal of Cancer, 139

J. Ohm, D. Gabrilovich, G. Sempowski, E. Kisseleva, K. Parman, S. Nadaf, D. Carbone (2003)

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

Blood, 101 12

(2018)

CABOSUN randomised trial): progressionfree survival by independent review and overall survival update

( LarkinJMGTykodiSSDonskovF, et al 949P-First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. Ann Oncol 2019; 30(Suppl. 5): v381–v382.)

LarkinJMGTykodiSSDonskovF, et al 949P-First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. Ann Oncol 2019; 30(Suppl. 5): v381–v382., LarkinJMGTykodiSSDonskovF, et al 949P-First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. Ann Oncol 2019; 30(Suppl. 5): v381–v382.

( HuangYGoelSDudaDG, et al Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943–2948.23440426)

HuangYGoelSDudaDG, et al Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943–2948.23440426

HuangYGoelSDudaDG, et al Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943–2948.23440426, HuangYGoelSDudaDG, et al Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943–2948.23440426

( ChoueiriTKHesselCHalabiS, et al Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 2018; 94: 115–125.29550566)

ChoueiriTKHesselCHalabiS, et al Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 2018; 94: 115–125.29550566, ChoueiriTKHesselCHalabiS, et al Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 2018; 94: 115–125.29550566

Jason Zhu, A. Armstrong, T. Friedlander, W. Kim, S. Pal, D. George, Tian Zhang (2018)

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Journal for Immunotherapy of Cancer, 6

S. Kusmartsev, E. Eruslanov, H. Kübler, T. Tseng, Y. Sakai, Z. Su, S. Kaliberov, A. Heiser, C. Rosser, P. Dahm, D. Siemann, J. Vieweg (2008)

Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma1

The Journal of Immunology, 181

( SeamanSStevensJYangMY, et al Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539–554.17560335)

SeamanSStevensJYangMY, et al Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539–554.17560335

SeamanSStevensJYangMY, et al Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539–554.17560335, SeamanSStevensJYangMY, et al Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539–554.17560335

R. Fisher, M. Gore, J. Larkin (2013)

Current and future systemic treatments for renal cell carcinoma.

Seminars in cancer biology, 23 1

T. Choueiri, R. Motzer (2017)

Systemic Therapy for Metastatic Renal-Cell Carcinoma.

The New England journal of medicine, 376 4

( VoronTColussiOMarcheteauE, et al VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139–148.25601652)

VoronTColussiOMarcheteauE, et al VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139–148.25601652

VoronTColussiOMarcheteauE, et al VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139–148.25601652, VoronTColussiOMarcheteauE, et al VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139–148.25601652

( KusmartsevSEruslanovEKüblerH, et al Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008; 181: 346–353.18566400)

KusmartsevSEruslanovEKüblerH, et al Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008; 181: 346–353.18566400, KusmartsevSEruslanovEKüblerH, et al Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008; 181: 346–353.18566400

( ChowdhurySMcDermottDFVossMH, et al A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2017; 35(Suppl. 15): 4506.)

ChowdhurySMcDermottDFVossMH, et al A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2017; 35(Suppl. 15): 4506., ChowdhurySMcDermottDFVossMH, et al A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2017; 35(Suppl. 15): 4506.

M. Keeler, E. Kessler, Brandon Bernard, S. Weisdack, K. Breaker, M. Wold, Donna Ertz, D. Weitzenkamp, T. Flaig, E. Lam (2019)

Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.

Journal of Clinical Oncology

Shaan Dudani, J. Graham, C. Wells, S. Pal, N. Dizman, F. Donskov, G. Bjarnason, A. Hansen, M. Iafolla, U. Vaishampayan, C. Porta, B. Beuselinck, Flora Yan, L. Wood, E. Liow, C. Kollmannsberger, T. Yuasa, C. Zhang, T. Choueiri, D. Heng (2019)

First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Journal of Clinical Oncology

R. Nadal, A. Mortazavi, M. Stein, S. Pal, N. Davarpanah, H. Parnes, Y. Ning, L. Cordes, M. Bagheri, L. Lindenberg, R. Thompson, S. Steinberg, Tina Moore, Tiffany Lancaster, M. Velez, E. Mena, R. Costello, D. Bottaro, W. Dahut, A. Apolo (2018)

Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.

Journal of Clinical Oncology, 36

( NickersonMLJaegerEShiY, et al Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726–4734.18676741)

NickersonMLJaegerEShiY, et al Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726–4734.18676741

NickersonMLJaegerEShiY, et al Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726–4734.18676741, NickersonMLJaegerEShiY, et al Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726–4734.18676741

E. Rassy, Rita Abboud, N. Ibrahim, T. Assi, F. Aoun, J. Kattan (2018)

The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer.

Immunotherapy, 10 12

( RiniBIPowlesTAtkinsMB, et al Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404–2415.31079938)

RiniBIPowlesTAtkinsMB, et al Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404–2415.31079938, RiniBIPowlesTAtkinsMB, et al Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404–2415.31079938

B. Escudier, T. Eisen, C. Porta, J. Patard, V. Khoo, F. Algaba, P. Mulders, V. Kataja (2012)

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 7

S. Chowdhury, D. McDermott, M. Voss, R. Hawkins, P. Aimone, M. Voi, Naëije Isabelle, Yi Wu, J. Infante (2017)

A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).

Journal of Clinical Oncology, 35

B. Rini, T. Powles, M. Atkins, B. Escudier, D. McDermott, C. Suarez, S. Bracarda, W. Stadler, F. Donskov, J. Lee, R. Hawkins, A. Ravaud, B. Alekseev, M. Staehler, M. Uemura, U. Giorgi, B. Mellado, C. Porta, B. Melichar, H. Gurney, J. Bedke, T. Choueiri, F. Parnis, T. Khaznadar, A. Thobhani, Shi Li, E. Piault-Louis, G. Frantz, M. Huseni, C. Schiff, Marjorie Green, R. Motzer (2019)

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet, 393

( HahnAWKlaassenZAgarwalN et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2019; 2(6): 708–715.)

HahnAWKlaassenZAgarwalN et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2019; 2(6): 708–715.

HahnAWKlaassenZAgarwalN et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2019; 2(6): 708–715., HahnAWKlaassenZAgarwalN et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2019; 2(6): 708–715.

Hua Huang, Elise Langenkamp, Maria Georganaki, A. Loskog, Peder Fuchs, L. Dieterich, J. Kreuger, A. Dimberg (2015)

VEGF suppresses T‐lymphocyte infiltration in the tumor microenvironment through inhibition of NF‐κB‐induced endothelial activation

The FASEB Journal, 29

( GabrilovichDIChenHLGirgisKR, et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.8837607)

GabrilovichDIChenHLGirgisKR, et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.8837607

GabrilovichDIChenHLGirgisKR, et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.8837607, GabrilovichDIChenHLGirgisKR, et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.8837607

R. Motzer, T. Powles, M. Atkins, B. Escudier, D. McDermott, C. Suarez, S. Bracarda, W. Stadler, F. Donskov, Jae-Lyun Lee, R. Hawkins, A. Ravaud, B. Alekseev, M. Staehler, M. Uemura, F. Donaldson, Shi Li, M. Huseni, C. Schiff, B. Rini (2018)

IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

Journal of Clinical Oncology, 36

N. Gavalas, M. Tsiatas, O. Tsitsilonis, E. Politi, K. Ioannou, A. Ziogas, A. Rodolakis, G. Vlahos, N. Thomakos, D. Haidopoulos, E. Terpos, A. Antsaklis, M. Dimopoulos, A. Bamias (2012)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

British Journal of Cancer, 107

( GriffioenAWDamenCAMartinottiS, et al Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111–1117.8640769)

GriffioenAWDamenCAMartinottiS, et al Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111–1117.8640769, GriffioenAWDamenCAMartinottiS, et al Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111–1117.8640769

( AounFRassyEEAssiT, et al PDL-1/PD1 inhibitors: antibody or antinobody? Future Oncol 2017; 13: 1669–1671.28831825)

AounFRassyEEAssiT, et al PDL-1/PD1 inhibitors: antibody or antinobody? Future Oncol 2017; 13: 1669–1671.28831825

AounFRassyEEAssiT, et al PDL-1/PD1 inhibitors: antibody or antinobody? Future Oncol 2017; 13: 1669–1671.28831825, AounFRassyEEAssiT, et al PDL-1/PD1 inhibitors: antibody or antinobody? Future Oncol 2017; 13: 1669–1671.28831825

( EscudierBBarthelemyPRavaudA, et al Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 618.)

EscudierBBarthelemyPRavaudA, et al Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 618.

EscudierBBarthelemyPRavaudA, et al Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 618., EscudierBBarthelemyPRavaudA, et al Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 618.

( FisherRGoreMLarkinJ. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013; 23: 38–45.22705280)

FisherRGoreMLarkinJ. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013; 23: 38–45.22705280

FisherRGoreMLarkinJ. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013; 23: 38–45.22705280, FisherRGoreMLarkinJ. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013; 23: 38–45.22705280

( ChoueiriTKAlbigesLHaanenJBAG, et al Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37(Suppl. 15): 101.)

ChoueiriTKAlbigesLHaanenJBAG, et al Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37(Suppl. 15): 101., ChoueiriTKAlbigesLHaanenJBAG, et al Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37(Suppl. 15): 101.

( ChoueiriTKLarkinJOyaM, et al Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol 2018; 19: 451–460.29530667)

ChoueiriTKLarkinJOyaM, et al Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol 2018; 19: 451–460.29530667, ChoueiriTKLarkinJOyaM, et al Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol 2018; 19: 451–460.29530667

M. Binnewies, Edward Roberts, K. Kersten, Vincent Chan, Douglas Fearon, M. Merad, L. Coussens, D. Gabrilovich, S. Ostrand-Rosenberg, S. Ostrand-Rosenberg, C. Hedrick, R. Vonderheide, M. Pittet, R. Jain, W. Zou, T. Howcroft, E. Woodhouse, R. Weinberg, M. Krummel (2018)

Understanding the tumor immune microenvironment (TIME) for effective therapy

Nature Medicine, 24

T. Curiel, Shuang Wei, Haidong Dong, Xavier Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. Knutson, B. Daniel, M. Zimmermann, O. David, M. Burow, Alan Gordon, N. Dhurandhar, L. Myers, R. Berggren, A. Hemminki, R. Alvarez, D. Émilie, D. Curiel, Lieping Chen, W. Zou (2003)

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

Nature Medicine, 9

R. Motzer, N. Tannir, D. McDermott, O. Frontera, B. Melichar, T. Choueiri, E. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M. Grimm, S. Bracarda, C. Barrios, Y. Tomita, D. Castellano, B. Rini, Allen Chen, S. Mekan, B. McHenry, M. Wind-Rotolo, J. Doan, P. Sharma, H. Hammers, B. Escudier (2018)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma

The New England Journal of Medicine, 378

G. Velasco, A. Bex, L. Albiges, T. Powles, B. Rini, R. Motzer, D. Heng, B. Escudier (2019)

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

European urology oncology

( MovahediKLaouiDGysemansC, et al Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728–5739.20570887)

MovahediKLaouiDGysemansC, et al Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728–5739.20570887

MovahediKLaouiDGysemansC, et al Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728–5739.20570887, MovahediKLaouiDGysemansC, et al Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728–5739.20570887

( AtkinsMBMcDermottDFPowlesT, et al IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 2017; 35(Suppl. 15): 4505.)

AtkinsMBMcDermottDFPowlesT, et al IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 2017; 35(Suppl. 15): 4505., AtkinsMBMcDermottDFPowlesT, et al IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 2017; 35(Suppl. 15): 4505.

( CurielTJWeiSDongH, et al Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.12704383)

CurielTJWeiSDongH, et al Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.12704383

CurielTJWeiSDongH, et al Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.12704383, CurielTJWeiSDongH, et al Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.12704383

( HuangYChenXDikovMM, et al Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624–631.17376891)

HuangYChenXDikovMM, et al Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624–631.17376891

HuangYChenXDikovMM, et al Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624–631.17376891, HuangYChenXDikovMM, et al Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624–631.17376891

T. Choueiri, J. Larkin, M. Oya, F. Thistlethwaite, M. Martignoni, P. Nathan, T. Powles, D. McDermott, P. Robbins, D. Chism, D. Cho, M. Atkins, M. Gordon, Sumati Gupta, H. Uemura, Y. Tomita, A. Compagnoni, C. Fowst, A. Pietro, B. Rini (2018)

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

The Lancet. Oncology, 19 4

T. Osada, Gabriel Chong, R. Tansik, Timothy Hong, N. Spector, Rakesh Kumar, Herbert Hurwitz, Inder Dev, A. Nixon, H. Lyerly, T. Clay, M. Morse (2008)

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

Cancer Immunology, Immunotherapy, 57

Satoshi Yasuda, Masayuki Sho, I. Yamato, Hitoshi Yoshiji, K. Wakatsuki, S. Nishiwada, H. Yagita, Yoshiyuki Nakajima (2013)

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo

Clinical & Experimental Immunology, 172

D. Gabrilovich, D. Gabrilovich, Hailei Chen, K. Girgis, H. Cunningham, G. Meny, S. Nadaf, S. Nadaf, D. Kavanaugh, D. Carbone, D. Carbone (1996)

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Nature Medicine, 2

( OsadaTChongGTansikR, et al The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115–1124.18193223)

OsadaTChongGTansikR, et al The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115–1124.18193223

OsadaTChongGTansikR, et al The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115–1124.18193223, OsadaTChongGTansikR, et al The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115–1124.18193223

( RufMMochHSchramlP. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 2016; 139: 396–403.26945902)

RufMMochHSchramlP. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 2016; 139: 396–403.26945902

RufMMochHSchramlP. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 2016; 139: 396–403.26945902, RufMMochHSchramlP. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 2016; 139: 396–403.26945902

S. Seaman, Janine Stevens, M. Yang, Daniel Logsdon, Cari Graff-Cherry, B. Croix (2007)

Genes that distinguish physiological and pathological angiogenesis.

Cancer cell, 11 6

( ZhuJArmstrongAJFriedlanderTW, et al Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer 2018; 6: 4.29368638)

ZhuJArmstrongAJFriedlanderTW, et al Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer 2018; 6: 4.29368638

ZhuJArmstrongAJFriedlanderTW, et al Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer 2018; 6: 4.29368638, ZhuJArmstrongAJFriedlanderTW, et al Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer 2018; 6: 4.29368638

B. Escudier, P. Barthélémy, A. Ravaud, S. Négrier, M. Needle, L. Albiges (2018)

Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology, 36

F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA: A Cancer Journal for Clinicians, 68

( BinnewiesMRobertsEWKerstenK, et al Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541–550.29686425)

BinnewiesMRobertsEWKerstenK, et al Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541–550.29686425

BinnewiesMRobertsEWKerstenK, et al Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541–550.29686425, BinnewiesMRobertsEWKerstenK, et al Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541–550.29686425

( ChenDSMellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.23890059)

ChenDSMellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.23890059

ChenDSMellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.23890059, ChenDSMellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.23890059

( RassyEEKhoury AbboudRMIbrahimN, et al The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. Immunotherapy 2018; 10: 1047–1052.30185138)

RassyEEKhoury AbboudRMIbrahimN, et al The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. Immunotherapy 2018; 10: 1047–1052.30185138

RassyEEKhoury AbboudRMIbrahimN, et al The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. Immunotherapy 2018; 10: 1047–1052.30185138, RassyEEKhoury AbboudRMIbrahimN, et al The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. Immunotherapy 2018; 10: 1047–1052.30185138

( TurajlicSLitchfieldKXuH, et al Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017; 18: 1009–1021.28694034)

TurajlicSLitchfieldKXuH, et al Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017; 18: 1009–1021.28694034

TurajlicSLitchfieldKXuH, et al Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017; 18: 1009–1021.28694034, TurajlicSLitchfieldKXuH, et al Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017; 18: 1009–1021.28694034

( HutsonTE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011; 16(Suppl. 2): 14–22.21346036)

HutsonTE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011; 16(Suppl. 2): 14–22.21346036

HutsonTE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011; 16(Suppl. 2): 14–22.21346036, HutsonTE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011; 16(Suppl. 2): 14–22.21346036

( AlfaroCSuarezNGonzalezA, et al Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100: 1111–1119.19277038)

AlfaroCSuarezNGonzalezA, et al Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100: 1111–1119.19277038, AlfaroCSuarezNGonzalezA, et al Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100: 1111–1119.19277038

( CurtiBD. Immunotherapy in advanced renal cancer — is cure possible? N Engl J Med 2018; 378: 1344–1345.29562143)

CurtiBD. Immunotherapy in advanced renal cancer — is cure possible? N Engl J Med 2018; 378: 1344–1345.29562143

CurtiBD. Immunotherapy in advanced renal cancer — is cure possible? N Engl J Med 2018; 378: 1344–1345.29562143, CurtiBD. Immunotherapy in advanced renal cancer — is cure possible? N Engl J Med 2018; 378: 1344–1345.29562143

( BarryREKrekW. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004; 10: 466–472.15350900)

BarryREKrekW. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004; 10: 466–472.15350900

BarryREKrekW. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004; 10: 466–472.15350900, BarryREKrekW. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004; 10: 466–472.15350900

P. Barata, A. Liaño, P. Mendiratta, V. Crolley, B. Szabados, L. Wood, Beth Zanick, Kimberly Allman, A. Tyler, Allison Martin, T. Gilligan, P. Grivas, M. Ornstein, Jorge Garcia, T. Powles, B. Rini (2018)

Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.

Journal of Clinical Oncology, 36

( KhanKAKerbelRS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15: 310–324.29434333)

KhanKAKerbelRS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15: 310–324.29434333

KhanKAKerbelRS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15: 310–324.29434333, KhanKAKerbelRS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15: 310–324.29434333

( AdoteviOPereHRavelP, et al A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991–998.20948437)

AdoteviOPereHRavelP, et al A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991–998.20948437, AdoteviOPereHRavelP, et al A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991–998.20948437

Gregory Motz, G. Coukos (2011)

The parallel lives of angiogenesis and immunosuppression: cancer and other tales

Nature Reviews Immunology, 11

( MotzerRJEscudierBMcDermottDF, et al Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–1813.26406148)

MotzerRJEscudierBMcDermottDF, et al Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–1813.26406148

MotzerRJEscudierBMcDermottDF, et al Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–1813.26406148, MotzerRJEscudierBMcDermottDF, et al Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–1813.26406148

( RiniBIHalabiSRosenbergJE, et al Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422–5428.18936475)

RiniBIHalabiSRosenbergJE, et al Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422–5428.18936475, RiniBIHalabiSRosenbergJE, et al Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422–5428.18936475

B. Rini, M. Huseni, M. Atkins, D. McDermott, T. Powles, B. Escudier, R. Banchereau, L-F Liu, N. Leng, J. Fan, J. Doss, S. Nalle, S. Carroll, Shi Li, C. Schiff, Marjorie Green, R. Motzer (2018)

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC).

Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8

Gregory Motz, Stephen Santoro, Li-ping Wang, T. Garrabrant, R. Lastra, I. Hagemann, P. Lal, M. Feldman, F. Benencia, G. Coukos (2014)

Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors

Nature medicine, 20

( KriegCNowickaMGugliettaS, et al High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018; 24: 144–153.29309059)

KriegCNowickaMGugliettaS, et al High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018; 24: 144–153.29309059

KriegCNowickaMGugliettaS, et al High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018; 24: 144–153.29309059, KriegCNowickaMGugliettaS, et al High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018; 24: 144–153.29309059

L. Albiges, T. Powles, M. Staehler, K. Bensalah, R. Giles, M. Hora, M. Kuczyk, T. Lam, B. Ljungberg, L. Marconi, A. Merseburger, A. Volpe, Y. Abu-Ghanem, S. Dabestani, S. Fernandez-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, A. Bex (2019)

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

European urology

O. Adotévi, H. Péré, P. Ravel, N. Haicheur, C. Badoual, N. Merillon, J. Medioni, S. Peyrard, S. Roncelin, V. Verkarre, A. Méjean, W. Fridman, S. Oudard, E. Tartour (2010)

A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients

Journal of Immunotherapy, 33

B. Rini, E. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. McDermott, J. Bedke, S. Tartas, Yen‐Hwa Chang, S. Tamada, Q. Shou, R. Perini, Mei Chen, M. Atkins, T. Powles (2019)

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

The New England Journal of Medicine, 380

( NadalRMMortazaviASteinM, et al Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J Clin Oncol 2018; 36(Suppl. 6): 515.29267131)

NadalRMMortazaviASteinM, et al Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J Clin Oncol 2018; 36(Suppl. 6): 515.29267131, NadalRMMortazaviASteinM, et al Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J Clin Oncol 2018; 36(Suppl. 6): 515.29267131

( MotzerRJHutsonTETomczakP, et al Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584–3590.19487381)

MotzerRJHutsonTETomczakP, et al Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584–3590.19487381, MotzerRJHutsonTETomczakP, et al Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584–3590.19487381

F. Aoun, E. Rassy, T. Assi, J. Kattan (2017)

PDL-1/PD1 inhibitors: antibody or antinobody?

Future oncology, 13 19

( ChoueiriTKMotzerRJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376: 354–366.28121507)

ChoueiriTKMotzerRJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376: 354–366.28121507

ChoueiriTKMotzerRJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376: 354–366.28121507, ChoueiriTKMotzerRJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376: 354–366.28121507

B. Escudier, A. Płużańska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, Marek Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J. Bay, I. Bodrogi, A. Jagiełło-Gruszfeld, N. Moore (2007)

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

The Lancet, 370

J. Larkin, S. Tykodi, F. Donskov, J. Lee, C. Szczylik, J. Malik, B. Alekseev, V. Matveev, R. Gafanov, P. Tomczak, P. Geertsen, P. Wiechno, S. Shin, F. Pouliot, T. Gordoa, R. Silverman, R. Perini, C. Schloss, D. McDermott, M. Atkins (2019)

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

Annals of Oncology

A. Amin, E. Plimack, J. Infante, M. Ernstoff, B. Rini, D. McDermott, J. Knox, S. Pal, M. Voss, P. Sharma, C. Kollmannsberger, D. Heng, J. Spratlin, Yun Shen, J. Kurland, P. Gagnier, H. Hammers (2014)

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology, 32

R. Motzer, B. Rini, D. McDermott, O. Frontera, H. Hammers, M. Carducci, P. Salman, B. Escudier, B. Beuselinck, A. Amin, C. Porta, S. George, V. Neiman, S. Bracarda, S. Tykodi, P. Barthélémy, R. Leibowitz-Amit, E. Plimack, S. Oosting, B. Redman, B. Melichar, T. Powles, P. Nathan, S. Oudard, D. Pook, T. Choueiri, F. Donskov, M. Grimm, H. Gurney, D. Heng, C. Kollmannsberger, M. Harrison, Y. Tomita, I. Durán, V. Grünwald, M. McHenry, S. Mekan, N. Tannir (2019)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology

( de VelascoGBexAAlbigesL, et al Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. Eur Urol Oncol 2019; 2(5): 505–514.31377308)

de VelascoGBexAAlbigesL, et al Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. Eur Urol Oncol 2019; 2(5): 505–514.31377308

de VelascoGBexAAlbigesL, et al Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. Eur Urol Oncol 2019; 2(5): 505–514.31377308, de VelascoGBexAAlbigesL, et al Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. Eur Urol Oncol 2019; 2(5): 505–514.31377308

( MotzerRJHutsonTECellaD, et al Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722–731.23964934)

MotzerRJHutsonTECellaD, et al Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722–731.23964934

MotzerRJHutsonTECellaD, et al Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722–731.23964934, MotzerRJHutsonTECellaD, et al Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722–731.23964934

M. Atkins, D. McDermott, T. Powles, R. Motzer, B. Rini, L. Fong, R. Joseph, S. Pal, M. Sznol, J. Hainsworth, W. Stadler, Thomas Hutson, A. Ravaud, S. Bracarda, C. Suarez, T. Choueiri, J. Qiu, M. Huseni, C. Schiff, B. Escudier (2017)

IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

Journal of Clinical Oncology, 35

A. Hahn, Z. Klaassen, N. Agarwal, B. Haaland, John Esther, X. Ye, Xue-chen Wang, S. Pal, C. Wallis (2019)

First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

European urology oncology

( HammersHJPlimackERInfanteJR, et al Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017; 35: 3851–3858.28678668)

HammersHJPlimackERInfanteJR, et al Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017; 35: 3851–3858.28678668, HammersHJPlimackERInfanteJR, et al Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017; 35: 3851–3858.28678668

C. Alfaro, Natalia Suárez, Álvaro González, Sarai Solano, Lorena Erro, J. Dubrot, A. Palazón, S. Hervás-Stubbs, A. Gúrpide, J. López-Picazo, E. Grande-Pulido, Ignacio Melero, J. Pérez-Gracia (2009)

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

British Journal of Cancer, 100

( GavalasNGTsiatasMTsitsilonisO, et al VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012; 107: 1869–1875.23169339)

GavalasNGTsiatasMTsitsilonisO, et al VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012; 107: 1869–1875.23169339

GavalasNGTsiatasMTsitsilonisO, et al VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012; 107: 1869–1875.23169339, GavalasNGTsiatasMTsitsilonisO, et al VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012; 107: 1869–1875.23169339

S. Négrier, E. Raymond (2012)

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma

Investigational New Drugs, 30

( NégrierSRaymondE. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012; 30: 1791–1801.21573959)

NégrierSRaymondE. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012; 30: 1791–1801.21573959

NégrierSRaymondE. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012; 30: 1791–1801.21573959, NégrierSRaymondE. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012; 30: 1791–1801.21573959

( OhmJEGabrilovichDISempowskiGD, et al VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878–4886.12586633)

OhmJEGabrilovichDISempowskiGD, et al VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878–4886.12586633

OhmJEGabrilovichDISempowskiGD, et al VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878–4886.12586633, OhmJEGabrilovichDISempowskiGD, et al VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878–4886.12586633

R. Motzer, K. Penkov, J. Haanen, B. Rini, L. Albiges, M. Campbell, B. Venugopal, C. Kollmannsberger, S. Négrier, M. Uemura, J. Lee, A. Vasiliev, W. Miller, H. Gurney, M. Schmidinger, J. Larkin, M. Atkins, J. Bedke, B. Alekseev, Jing Wang, M. Mariani, P. Robbins, A. Chudnovsky, C. Fowst, S. Hariharan, B. Huang, A. Pietro, T. Choueiri (2019)

Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

The New England Journal of Medicine, 380

T. Choueiri, C. Hessel, S. Halabi, B. Sanford, M. Michaelson, O. Hahn, Meghara Walsh, T. Olencki, J. Picus, E. Small, S. Dakhil, D. Feldman, M. Mangeshkar, C. Scheffold, D. George, M. Morris (2018)

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

European journal of cancer (Oxford, England : 1990), 94

( RiniBIPlimackERStusV, et al Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116–1127.30779529)

RiniBIPlimackERStusV, et al Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116–1127.30779529

RiniBIPlimackERStusV, et al Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116–1127.30779529, RiniBIPlimackERStusV, et al Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116–1127.30779529

( PalazónAAragonésJMorales-KastresanaA, et al Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012; 18: 1207–1213.22205687)

PalazónAAragonésJMorales-KastresanaA, et al Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012; 18: 1207–1213.22205687

PalazónAAragonésJMorales-KastresanaA, et al Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012; 18: 1207–1213.22205687, PalazónAAragonésJMorales-KastresanaA, et al Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012; 18: 1207–1213.22205687

( MotzerRJPenkovKHaanenJ, et al Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1103–1115.30779531)

MotzerRJPenkovKHaanenJ, et al Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1103–1115.30779531

MotzerRJPenkovKHaanenJ, et al Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1103–1115.30779531, MotzerRJPenkovKHaanenJ, et al Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1103–1115.30779531

B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena, S. Ou, L. Archer, J. Atkins, J. Picus, P. Czaykowski, J. Dutcher, E. Small (2008)

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33

( PittetCLNewcombeJPratA, et al Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011; 8: 155.22067141)

PittetCLNewcombeJPratA, et al Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011; 8: 155.22067141

PittetCLNewcombeJPratA, et al Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011; 8: 155.22067141, PittetCLNewcombeJPratA, et al Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011; 8: 155.22067141

A. Griffioen, C. Damen, Stefano Martinotti, Geert Blijham, Gerard Groenewegen (1996)

Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.

Cancer research, 56 5

( LeeCHMakkerVRascoDW, et al Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. J Clin Oncol 2018; 36(Suppl. 15): 4560.)

LeeCHMakkerVRascoDW, et al Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. J Clin Oncol 2018; 36(Suppl. 15): 4560.

LeeCHMakkerVRascoDW, et al Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. J Clin Oncol 2018; 36(Suppl. 15): 4560., LeeCHMakkerVRascoDW, et al Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. J Clin Oncol 2018; 36(Suppl. 15): 4560.

R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Yoshihiko Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, P. Sharma (2015)

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

The New England journal of medicine, 373 19

( BarataPCGomez de LianoAMendirattaP, et al Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens. J Clin Oncol 2018; 36(Suppl. 6): 613.)

BarataPCGomez de LianoAMendirattaP, et al Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens. J Clin Oncol 2018; 36(Suppl. 6): 613., BarataPCGomez de LianoAMendirattaP, et al Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens. J Clin Oncol 2018; 36(Suppl. 6): 613.

Yuhui Huang, Xiaolan Chen, M. Dikov, S. Novitskiy, C. Mosse, Li Yang, D. Carbone (2007)

Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.

Blood, 110 2

( MotzerRJRiniBIMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20: 1370–1385.31427204)

MotzerRJRiniBIMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20: 1370–1385.31427204, MotzerRJRiniBIMcDermottDF, et al Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20: 1370–1385.31427204

( RiniBIHuseniMAtkinsMB, et al LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Ann Oncol 2018; 29(Suppl. 8). DOI: 10.1093/annonc/mdy424.037.)

RiniBIHuseniMAtkinsMB, et al LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Ann Oncol 2018; 29(Suppl. 8). DOI: 10.1093/annonc/mdy424.037., RiniBIHuseniMAtkinsMB, et al LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Ann Oncol 2018; 29(Suppl. 8). DOI: 10.1093/annonc/mdy424.037.

G. Bergers, D. Hanahan (2008)

Modes of resistance to anti-angiogenic therapy

Nature Reviews Cancer, 8

K. Movahedi, Damya Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Bossche, M. Mack, D. Pipeleers, P. Veld, P. Baetselier, J. Ginderachter (2010)

Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.

Cancer research, 70 14

( BergersGHanahanD. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.18650835)

BergersGHanahanD. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.18650835

BergersGHanahanD. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.18650835, BergersGHanahanD. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.18650835

( MotzGTCoukosG. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702–711.21941296)

MotzGTCoukosG. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702–711.21941296

MotzGTCoukosG. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702–711.21941296, MotzGTCoukosG. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702–711.21941296

Yuhui Huang, S. Goel, D. Duda, D. Fukumura, R. Jain (2013)

Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

Cancer research, 73 10

M. Nickerson, Erich Jaeger, Yangu Shi, J. Durocher, S. Mahurkar, D. Zaridze, V. Matveev, V. Janout, H. Kollarova, V. Bencko, M. Navratilova, N. szeszenia-Dabrowska, D. Mates, A. Mukeria, I. Holcatova, L. Schmidt, J. Toro, S. Karami, R. Hung, G. Gerard, W. Linehan, M. Merino, B. Zbar, P. Boffetta, P. Brennan, N. Rothman, W. Chow, F. Waldman, L. Moore (2008)

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

Clinical Cancer Research, 14

C. Krieg, M. Nowicka, S. Guglietta, Sabrina Schindler, F. Hartmann, L. Weber, R. Dummer, M. Robinson, M. Levesque, B. Becher (2018)

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Nature Medicine, 24

Shaan Dudani, J. Graham, J. Wells, Ziad Bakouny, S. Pal, N. Dizman, F. Donskov, C. Porta, G. Velasco, A. Hansen, M. Iafolla, B. Beuselinck, U. Vaishampayan, L. Wood, E. Liow, Flora Yan, T. Yuasa, G. Bjarnason, T. Choueiri, D. Heng (2019)

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

European urology

( TianLGoldsteinAWangH, et al Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017; 544: 250–254.28371798)

TianLGoldsteinAWangH, et al Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017; 544: 250–254.28371798

TianLGoldsteinAWangH, et al Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017; 544: 250–254.28371798, TianLGoldsteinAWangH, et al Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017; 544: 250–254.28371798

M. Atkins, E. Plimack, I. Puzanov, M. Fishman, D. McDermott, D. Cho, U. Vaishampayan, S. George, T. Olencki, J. Tarazi, B. Rosbrook, Kathrine Fernandez, M. Lechuga, T. Choueiri (2018)

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

The Lancet. Oncology, 19 3

Camille Pittet, J. Newcombe, A. Prat, N. Arbour (2011)

Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis

Journal of Neuroinflammation, 8

Visit SAGE journals online journals.sagepub.com/ home/tam

Kabir Khan, R. Kerbel (2018)

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Nature Reviews Clinical Oncology, 15

( KeelerMEKesslerERBernardB, et al Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): phase I results. J Clin Oncol 2019; 37(Suppl. 7): 600.)

KeelerMEKesslerERBernardB, et al Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): phase I results. J Clin Oncol 2019; 37(Suppl. 7): 600.

KeelerMEKesslerERBernardB, et al Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): phase I results. J Clin Oncol 2019; 37(Suppl. 7): 600., KeelerMEKesslerERBernardB, et al Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): phase I results. J Clin Oncol 2019; 37(Suppl. 7): 600.

R. Barry, W. Krek (2004)

The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.

Trends in molecular medicine, 10 9

T. Choueiri, L. Albiges, J. Haanen, J. Larkin, M. Uemura, S. Pal, G. Gravis, M. Campbell, K. Penkov, Jae-Lyun Lee, K. Ching, X. Mu, Xiao Wang, Weidong Zhang, Jing Wang, A. Chudnovsky, A. Pietro, P. Robbins, R. Motzer (2019)

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Journal of Clinical Oncology

S. Turajlic, K. Litchfield, Hang Xu, R. Rosenthal, N. Mcgranahan, J. Reading, Y. Wong, A. Rowan, N. Kanu, M. Bakir, T. Chambers, R. Salgado, P. Savas, S. Loi, N. Birkbak, Laurent Sansregret, M. Gore, J. Larkin, S. Quezada, C. Swanton (2017)

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

The Lancet. Oncology, 18 8

( MotzGTSantoroSPWangLP, et al Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607–615.24793239)

MotzGTSantoroSPWangLP, et al Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607–615.24793239

MotzGTSantoroSPWangLP, et al Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607–615.24793239, MotzGTSantoroSPWangLP, et al Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607–615.24793239

( McDermottDFHuseniMAAtkinsMB, et al Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018; 24: 749–757.29867230)

McDermottDFHuseniMAAtkinsMB, et al Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018; 24: 749–757.29867230, McDermottDFHuseniMAAtkinsMB, et al Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018; 24: 749–757.29867230

Chung-Han Lee, V. Makker, D. Rasco, Matthew Taylor, D. Stepan, R. Shumaker, E. Schmidt, M. Guo, C. Dutcus, R. Motzer (2018)

Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.

Journal of Clinical Oncology, 36

A. Palazón, Julián Aragonés, A. Morales-Kastresana, M. Landázuri, I. Melero (2011)

Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer

Clinical Cancer Research, 18

Lin Tian, A. Goldstein, Hai Wang, H. Lo, I. Kim, T. Welte, Kuanwei Sheng, L. Dobrolecki, Xiaomei Zhang, N. Putluri, T. Phung, Sendurai Mani, F. Stossi, A. Sreekumar, M. Mancini, W. Decker, Chenghang Zong, M. Lewis, X. Zhang (2017)

Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming

Nature, 544

( MotzerRJPowlesTAtkinsMB, et al IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 578.)

MotzerRJPowlesTAtkinsMB, et al IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 578., MotzerRJPowlesTAtkinsMB, et al IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; 36(Suppl. 6): 578.

R. Motzer, Thomas Hutson, P. Tomczak, M. Michaelson, R. Bukowski, S. Oudard, S. Négrier, C. Szczylik, R. Pili, G. Bjarnason, X. Garcia-Del-Muro, J. Sosman, E. Solska, G. Wilding, John Thompson, Sindy Kim, I. Chen, Xin Huang, R. Figlin (2009)

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of Clinical Oncology, 41

D. Hanahan, R. Weinberg (2011)

Hallmarks of Cancer: The Next Generation

Cell, 144

( HuangHLangenkampEGeorganakiM, et al VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J 2015; 29: 227–238.25361735)

HuangHLangenkampEGeorganakiM, et al VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J 2015; 29: 227–238.25361735, HuangHLangenkampEGeorganakiM, et al VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J 2015; 29: 227–238.25361735

( EscudierBPluzanskaAKoralewskiP, et al Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103–2111.18156031)

EscudierBPluzanskaAKoralewskiP, et al Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103–2111.18156031, EscudierBPluzanskaAKoralewskiP, et al Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103–2111.18156031

( AminAPlimackERInfanteJR, et al Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32(Suppl. 15): 5010.)

AminAPlimackERInfanteJR, et al Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32(Suppl. 15): 5010., AminAPlimackERInfanteJR, et al Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32(Suppl. 15): 5010.

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma:

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma: